Hub : Traits :

Number of self-reported non-cancer illnesses

63 significantly associated models · 24 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 11626858 12156236 1 1 6.8e-08 3.8e-07 7.1e-01 100 CLCN6
2 1 71163715 73435171 1 1 1.1e-07 1.3e-09 5.0e-04 67 NEGR1
3 1 220314945 221696457 1 1 1.9e-07 1.3e-06 6.4e-01 99 RP11-295M18.6
4 2 27467598 27949052 1 1 3.7e-08 4.5e-08 1.0e+00 100 FNDC4
5 2 102118712 103555146 1 1 2.6e-07 1.4e-07 1.2e-03 62 IL1RL2
6 5 131008194 132425049 1 1 4.8e-08 1.9e-08 7.6e-04 64 SLC22A5
7 7 1580921 2977732 1 1 1.5e-09 2.6e-13 2.4e-06 58 FTSJ2
8 7 73425238 74494207 2 1 3.4e-09 1.0e-06 4.8e-01 98 STAG3L2
9 12 111154626 113517494 3 1 4.6e-10 6.8e-12 2.3e-04 71 SH2B3
10 15 66797492 68789191 3 1 2.0e-09 7.1e-11 5.9e-04 72 IQCH
11 17 37386899 38783469 2 1 8.1e-08 1.6e-06 7.0e-01 99 GSDMB
12 17 46888301 48347817 2 2 2.5e-09 2.0e-10 1.6e-02 86 RP5-1029K10.2 ZNF652
13 20 57525478 58079512 1 1 3.2e-10 5.7e-11 2.2e-03 78 ZNF831
14 20 61576647 62912463 1 1 3.0e-07 1.2e-06 1.3e-06 1 STMN3

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 2.61 2 0 0.0 0.00 1.0e+00 FNDC4 GSDMB
Bipolar Disorder or Schizophrenia 2.03 3 0 0.0 0.00 1.0e+00 CLCN6 FTSJ2 GSDMB
Depressed Affect (Nagel 2018) 2.37 2 1 2.2 0.00 1.0e+00 FTSJ2 SH2B3
Depression (Nagel 2018) 2.68 1 0 0.0 0.00 1.0e+00 FTSJ2
Intelligence (Savage-Jansen 2018) 3.16 1 1 2.2 0.00 1.0e+00 NEGR1
Neuroticism (Nagel 2018) 1.75 1 1 2.2 0.00 1.0e+00 FTSJ2
Schizophrenia vs Biploar Disorder 2.47 2 0 0.0 0.00 1.0e+00 FNDC4 GSDMB
Worry (Nagel 2018) 1.35 2 0 0.0 0.00 1.0e+00 FTSJ2 IQCH
Crohns Disease (2017) 6.18 4 3 6.7 -0.33 6.7e-01 FNDC4 GSDMB STAG3L2 STMN3
Irritable Bowel Disease (IBD) 7.35 5 3 6.7 0.07 9.1e-01 FNDC4 GSDMB SH2B3 STAG3L2 STMN3
Ulcerative Colitis (UC) 4.90 3 2 4.4 0.00 1.0e+00 GSDMB STAG3L2 STMN3
Major Depression (MDD) 3.30 1 1 2.2 0.00 1.0e+00 NEGR1
Reaction Time 3.10 1 1 2.2 0.00 1.0e+00 SH2B3
Verbal and Numeric Reasoning (VNR) 3.14 1 1 2.2 0.00 1.0e+00 NEGR1
Breast Cancer 1.60 1 0 0.0 0.00 1.0e+00 STAG3L2
Age at First Birth 2.02 1 0 0.0 0.00 1.0e+00 ZNF652
Body Mass Index (BMI) (2010) 4.49 1 1 2.2 0.00 1.0e+00 NEGR1
Coronary Artery Disease (CAD) 2.97 1 0 0.0 0.00 1.0e+00 SH2B3
Crohns Disease (2012) 4.00 3 1 2.2 0.00 1.0e+00 FNDC4 GSDMB STMN3
Mean Putamen Volume 2.15 1 0 0.0 0.00 1.0e+00 RP11-295M18.6
Fasting Glucose 5.89 1 1 2.2 0.00 1.0e+00 FNDC4
HDL Cholesterol 2.76 1 1 2.2 0.00 1.0e+00 GSDMB
LDL Cholesterol 2.40 2 0 0.0 0.00 1.0e+00 FNDC4 SH2B3
Lupus 2.32 2 0 0.0 0.00 1.0e+00 GSDMB SH2B3
Neuroticism (2016) 1.28 1 0 0.0 0.00 1.0e+00 FTSJ2
Primary Biliary Cirrhosis 4.82 3 2 4.4 0.00 1.0e+00 FNDC4 GSDMB SH2B3
Rheumatoid Arthritis 3.26 2 0 0.0 0.00 1.0e+00 GSDMB SH2B3
Triglycerides 26.97 2 1 2.2 0.00 1.0e+00 FNDC4 ZNF652
Ulcerative Colitis 4.10 2 2 4.4 0.00 1.0e+00 GSDMB STMN3
Blood Eosinophil Count 23.99 9 6 13.3 0.78 1.2e-02 CLCN6 GSDMB IL1RL2 IQCH RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Blood Platelet Count 5.90 6 5 11.1 0.72 1.0e-01 CLCN6 FNDC4 GSDMB RP5-1029K10.2 SH2B3 STMN3
Blood Red Count 2.99 7 3 6.7 0.62 1.4e-01 CLCN6 FNDC4 GSDMB SH2B3 STAG3L2 STMN3 ZNF652
Blood White Count 17.44 7 6 13.3 0.82 2.4e-02 FNDC4 GSDMB RP5-1029K10.2 SH2B3 SLC22A5 STMN3 ZNF652
Heel T-Score 1.12 3 2 4.4 0.00 1.0e+00 IQCH NEGR1 STAG3L2
BMI 4.00 7 4 8.9 0.65 1.1e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2 ZNF652
Height 2.18 9 8 17.8 -0.55 1.3e-01 FNDC4 FTSJ2 IQCH RP11-295M18.6 RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Waist Hip Ratio (WHR) 1.19 1 1 2.2 0.00 1.0e+00 IQCH
Systolic Blood Pressure 11.94 8 5 11.1 0.83 1.1e-02 CLCN6 FNDC4 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
Smoking Status 2.34 3 0 0.0 0.00 1.0e+00 IQCH STMN3 ZNF652
Allergy or Eczema 10.30 11 4 8.9 0.81 2.7e-03 CLCN6 FNDC4 GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SH2B3 SLC22A5 STMN3 ZNF652
Cardiovascular Disease 12.95 12 7 15.6 0.94 3.7e-06 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
Hypothyroidism (self reported) 8.48 1 1 2.2 0.00 1.0e+00 SH2B3
Respiratory disease 18.82 8 6 13.3 0.90 2.6e-03 GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Type 2 Diabetes (T2D) (2018) 4.62 3 1 2.2 0.00 1.0e+00 FNDC4 SH2B3 STMN3
Lung FEV1/FVC ratio 2.50 5 2 4.4 -0.99 1.9e-03 GSDMB IL1RL2 NEGR1 RP5-1029K10.2 ZNF652
Lung FVC 2.94 5 2 4.4 0.05 9.4e-01 FNDC4 GSDMB IQCH SH2B3 STMN3
Neuroticism 2.10 2 1 2.2 0.00 1.0e+00 FTSJ2 IQCH
Hair Pigment 0.55 3 2 4.4 0.00 1.0e+00 FNDC4 SH2B3 ZNF831
Tanning 0.54 3 1 2.2 0.00 1.0e+00 FNDC4 NEGR1 SH2B3
Hand grip strength (left) 1.18 2 0 0.0 0.00 1.0e+00 FNDC4 SLC22A5
Number of treatments/medications taken 9.91 11 4 8.9 0.99 2.1e-09 FNDC4 FTSJ2 IL1RL2 NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 SLC22A5 STAG3L2 ZNF652 ZNF831
Average weekly spirits intake 1.44 1 0 0.0 0.00 1.0e+00 FTSJ2
Sensitivity / hurt feelings 1.42 1 0 0.0 0.00 1.0e+00 IQCH
Relative age of first facial hair 3.07 4 1 2.2 0.07 9.3e-01 FNDC4 NEGR1 SLC22A5 STAG3L2
Other serious medical condition/disability diagnosed by doctor 3.56 2 0 0.0 0.00 1.0e+00 NEGR1 STAG3L2
Systolic blood pressure, automated reading 8.88 6 3 6.7 0.89 1.8e-02 CLCN6 RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF831
Angina 3.95 1 1 2.2 0.00 1.0e+00 ZNF652
Vitamin and mineral supplements 2.27 2 0 0.0 0.00 1.0e+00 FTSJ2 NEGR1
Medication: Metformin 3.00 1 1 2.2 0.00 1.0e+00 FNDC4
Diabetes (father) 2.54 1 0 0.0 0.00 1.0e+00 FNDC4
Diabetes (mother) 1.91 1 0 0.0 0.00 1.0e+00 FNDC4
Pack years adult smoking proportion 2.40 2 0 0.0 0.00 1.0e+00 STAG3L2 STMN3
Impedance of leg (right) 4.36 5 4 8.9 -0.53 3.5e-01 FNDC4 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Leg fat-free mass (left) 3.28 6 2 4.4 -0.26 6.2e-01 FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Trunk fat percentage 3.30 5 2 4.4 0.76 1.4e-01 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Hand grip strength (right) 1.35 2 0 0.0 0.00 1.0e+00 FNDC4 SLC22A5
Current tobacco smoking 2.91 2 1 2.2 0.00 1.0e+00 NEGR1 STMN3
Maternal smoking around birth 1.27 1 0 0.0 0.00 1.0e+00 IQCH
Fed-up feelings 2.03 1 1 2.2 0.00 1.0e+00 SH2B3
Frequency of unenthusiasm / disinterest in last 2 weeks 2.41 1 0 0.0 0.00 1.0e+00 FTSJ2
Relative age voice broke 2.60 1 0 0.0 0.00 1.0e+00 STAG3L2
Taking other prescription medications 10.30 10 2 4.4 0.99 1.1e-07 FTSJ2 GSDMB IL1RL2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Age when periods started (menarche) 4.66 4 2 4.4 -0.96 4.0e-02 IQCH NEGR1 STAG3L2 ZNF652
Heel bone mineral density (BMD) T-score, automated (left) 0.94 1 0 0.0 0.00 1.0e+00 IQCH
High blood pressure 10.84 8 5 11.1 0.96 1.4e-04 CLCN6 IQCH NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Hayfever, allergic rhinitis or eczema 10.05 8 4 8.9 0.92 1.1e-03 FNDC4 GSDMB IL1RL2 NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Multivitamins +/- minerals 2.85 2 0 0.0 0.00 1.0e+00 FTSJ2 NEGR1
Stomach or abdominal pain in last month 1.37 1 0 0.0 0.00 1.0e+00 NEGR1
Medication: Atenolol 4.71 2 1 2.2 0.00 1.0e+00 CLCN6 SH2B3
Medication: Levothyroxine sodium 6.90 1 1 2.2 0.00 1.0e+00 SH2B3
Sitting height 2.12 5 3 6.7 -0.64 2.5e-01 FNDC4 RP5-1029K10.2 SLC22A5 ZNF652 ZNF831
Chronic bronchitis/emphysema (father) 2.46 1 0 0.0 0.00 1.0e+00 IQCH
High blood pressure (mother) 3.73 2 0 0.0 0.00 1.0e+00 CLCN6 ZNF831
Body mass index (BMI) 3.67 6 3 6.7 0.62 1.9e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Impedance of leg (left) 4.31 6 3 6.7 -0.51 3.0e-01 FNDC4 FTSJ2 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Leg predicted mass (left) 3.30 6 2 4.4 -0.26 6.3e-01 FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Trunk fat mass 3.41 5 2 4.4 0.76 1.3e-01 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Waist circumference 3.85 5 3 6.7 0.73 1.6e-01 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Past tobacco smoking 3.23 3 1 2.2 0.00 1.0e+00 IQCH SH2B3 ZNF652
Alcohol usually taken with meals 2.44 2 0 0.0 0.00 1.0e+00 NEGR1 ZNF652
Nervous feelings 1.58 1 0 0.0 0.00 1.0e+00 IQCH
Forced vital capacity (FVC) 1.53 2 2 4.4 0.00 1.0e+00 IQCH STMN3
Heel bone mineral density (BMD) T-score, automated (right) 1.17 1 0 0.0 0.00 1.0e+00 IQCH
Qualifications: None of the above 3.27 3 1 2.2 0.00 1.0e+00 NEGR1 RP5-1029K10.2 STAG3L2
Mouth/teeth dental problems 1.57 1 0 0.0 0.00 1.0e+00 STAG3L2
Heart attack 4.92 4 0 0.0 0.99 6.7e-03 RP5-1029K10.2 SH2B3 ZNF652 ZNF831
Allergy 15.19 8 6 13.3 -0.93 9.9e-04 GSDMB IL1RL2 IQCH NEGR1 RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Diabetes (self-reported) 4.01 3 1 2.2 0.00 1.0e+00 FNDC4 STAG3L2 STMN3
Hayfever/allergic rhinitis (self-reported) 5.20 3 2 4.4 0.00 1.0e+00 GSDMB IL1RL2 RP11-295M18.6
Medication: Ramipril 4.51 4 0 0.0 1.00 1.6e-03 SH2B3 STAG3L2 STMN3 ZNF652
Medication: Simvastatin 5.44 4 1 2.2 0.97 3.3e-02 CLCN6 FNDC4 FTSJ2 ZNF831
Fluid intelligence score 2.73 1 1 2.2 0.00 1.0e+00 NEGR1
Illnesses of siblings 4.35 2 0 0.0 0.00 1.0e+00 CLCN6 SH2B3
Neuroticism score 2.07 2 0 0.0 0.00 1.0e+00 FTSJ2 IQCH
Weight 3.58 7 4 8.9 0.10 8.3e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 SH2B3 STAG3L2
Impedance of arm (right) 4.39 6 3 6.7 -0.16 7.6e-01 FNDC4 NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Arm fat percentage (right) 3.55 5 3 6.7 0.79 1.1e-01 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2
Trunk fat-free mass 3.57 4 2 4.4 -0.90 9.6e-02 FNDC4 NEGR1 SH2B3 SLC22A5
Hip circumference 3.65 7 5 11.1 0.12 7.9e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 SH2B3 STAG3L2
Alcohol intake versus 10 years previously 4.48 3 1 2.2 0.00 1.0e+00 FNDC4 FTSJ2 NEGR1
Father's age at death 2.45 1 1 2.2 0.00 1.0e+00 SH2B3
Worrier / anxious feelings 1.26 1 0 0.0 0.00 1.0e+00 FTSJ2
Frequency of tiredness / lethargy in last 2 weeks 2.12 2 0 0.0 0.00 1.0e+00 FTSJ2 SH2B3
Forced expiratory volume in 1-second (FEV1) 1.34 3 0 0.0 0.00 1.0e+00 IQCH SLC22A5 STMN3
Pulse rate 2.54 1 1 2.2 0.00 1.0e+00 FNDC4
Qualifications: A levels/AS levels or equivalent 2.78 2 1 2.2 0.00 1.0e+00 FTSJ2 NEGR1
Mouth/teeth dental problems: Dentures 3.11 4 0 0.0 0.01 9.9e-01 FNDC4 GSDMB NEGR1 STAG3L2
Asthma 18.66 6 5 11.1 0.92 8.3e-03 GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 ZNF652
Medication: Cholesterol lowering 6.27 3 1 2.2 0.00 1.0e+00 CLCN6 FNDC4 ZNF831
Medication: Lansoprazole 1.78 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of mother 2.90 2 0 0.0 0.00 1.0e+00 ZNF652 ZNF831
Forced expiratory volume in 1-second (FEV1), Best measure 1.24 2 0 0.0 0.00 1.0e+00 SLC22A5 STMN3
Impedance of arm (left) 4.60 6 2 4.4 -0.13 8.0e-01 FNDC4 NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652
Arm fat mass (right) 3.66 6 3 6.7 0.66 1.5e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Trunk predicted mass 3.60 4 2 4.4 -0.90 9.9e-02 FNDC4 NEGR1 SH2B3 SLC22A5
Standing height 2.23 8 6 13.3 -0.56 1.5e-01 FNDC4 FTSJ2 IQCH RP5-1029K10.2 SH2B3 SLC22A5 ZNF652 ZNF831
Tense / 'highly strung' 1.18 1 0 0.0 0.00 1.0e+00 FTSJ2
Seen doctor (GP) for nerves, anxiety, tension or depression 4.37 3 1 2.2 0.00 1.0e+00 FTSJ2 NEGR1 STMN3
Hair/balding pattern: Pattern 4 1.30 2 0 0.0 0.00 1.0e+00 IQCH SLC22A5
Birth weight of first child 5.27 2 2 4.4 0.00 1.0e+00 CLCN6 SH2B3
Blood clot in the leg (DVT) 1.74 1 0 0.0 0.00 1.0e+00 SH2B3
Headache pain in last month 3.07 2 0 0.0 0.00 1.0e+00 IQCH ZNF652
Medication for cholesterol, blood pressure or diabetes 8.25 7 3 6.7 -0.98 1.7e-04 CLCN6 FNDC4 NEGR1 SH2B3 STAG3L2 ZNF652 ZNF831
Gout (self-reported) 9.03 3 1 2.2 0.00 1.0e+00 FNDC4 IL1RL2 SH2B3
Hypothyroidism/myxoedema (self-reported) 6.99 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Amlodipine 3.24 2 1 2.2 0.00 1.0e+00 CLCN6 ZNF831
Medication: Ventolin 100micrograms inhaler 9.27 5 2 4.4 0.97 7.4e-03 GSDMB IL1RL2 IQCH SLC22A5 ZNF652
Birth weight 1.99 2 1 2.2 0.00 1.0e+00 CLCN6 SH2B3
High blood pressure (siblings) 4.90 3 1 2.2 0.00 1.0e+00 CLCN6 FNDC4 SH2B3
Forced vital capacity (FVC), Best measure 1.38 2 1 2.2 0.00 1.0e+00 IQCH STMN3
Body fat percentage 3.69 6 3 6.7 0.81 5.1e-02 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Leg fat percentage (right) 3.50 6 2 4.4 0.79 6.4e-02 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Arm fat-free mass (right) 3.79 3 3 6.7 0.00 1.0e+00 FNDC4 NEGR1 SH2B3
Exposure to tobacco smoke outside home 1.97 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 5.08 4 2 4.4 0.92 7.7e-02 FNDC4 IQCH NEGR1 ZNF652
Worry too long after embarrassment 1.69 1 0 0.0 0.00 1.0e+00 IQCH
Seen a psychiatrist for nerves, anxiety, tension or depression 1.71 1 0 0.0 0.00 1.0e+00 NEGR1
Wheeze or whistling in the chest in last year 7.28 7 2 4.4 0.96 6.6e-04 GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 STMN3 ZNF652
Qualifications: College or University degree 3.62 3 1 2.2 0.00 1.0e+00 FTSJ2 NEGR1 STMN3
Medication for pain relief, constipation, heartburn 2.83 2 0 0.0 0.00 1.0e+00 IL1RL2 ZNF831
Medication: Blood pressure 8.65 6 4 8.9 0.97 1.1e-03 CLCN6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Angina (self-reported) 3.62 1 0 0.0 0.00 1.0e+00 ZNF652
Medication: Allopurinol 7.71 2 1 2.2 0.00 1.0e+00 FNDC4 SH2B3
Medication: Seretide 50 evohaler 5.04 3 0 0.0 0.00 1.0e+00 GSDMB SLC22A5 ZNF652
Mean time to correctly identify matches 2.98 1 1 2.2 0.00 1.0e+00 SH2B3
Whole body fat mass 3.67 6 3 6.7 0.70 1.2e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Leg fat mass (right) 3.87 6 3 6.7 0.65 1.6e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Arm predicted mass (right) 3.82 3 3 6.7 0.00 1.0e+00 FNDC4 NEGR1 SH2B3
Pulse rate, automated reading 4.44 3 2 4.4 0.00 1.0e+00 FNDC4 NEGR1 STAG3L2
Alcohol intake frequency. 7.62 5 2 4.4 0.93 2.2e-02 FNDC4 FTSJ2 GSDMB NEGR1 STAG3L2
Comparative height size at age 10 2.62 5 3 6.7 -0.34 5.8e-01 FNDC4 IQCH SH2B3 SLC22A5 STAG3L2
Suffer from 'nerves' 0.94 1 0 0.0 0.00 1.0e+00 IQCH
Overall health rating 4.19 6 1 2.2 0.99 2.8e-04 FTSJ2 IQCH RP5-1029K10.2 STAG3L2 ZNF652 ZNF831
Chest pain or discomfort 3.42 2 0 0.0 0.00 1.0e+00 GSDMB RP5-1029K10.2
Had major operations 3.17 1 0 0.0 0.00 1.0e+00 ZNF652
Commuting to job workplace: Car/motor vehicle 1.65 1 0 0.0 0.00 1.0e+00 NEGR1
Medication: Aspirin 4.48 3 0 0.0 0.00 1.0e+00 FTSJ2 SH2B3 ZNF831
Supplements: Vitamin C 1.82 1 0 0.0 0.00 1.0e+00 GSDMB
Hypertension (Self-reported) 10.31 8 5 11.1 0.96 1.8e-04 CLCN6 IQCH NEGR1 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Illnesses of father: Heart disease 2.78 2 0 0.0 0.00 1.0e+00 FNDC4 SH2B3
Smoking status: Previous 3.07 2 0 0.0 0.00 1.0e+00 IQCH SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.69 1 0 0.0 0.00 1.0e+00 SLC22A5
Whole body fat-free mass 3.53 4 3 6.7 -0.87 1.3e-01 FNDC4 NEGR1 SH2B3 SLC22A5
Leg fat-free mass (right) 3.17 6 2 4.4 -0.29 5.7e-01 FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Arm fat percentage (left) 3.48 4 4 8.9 0.98 2.4e-02 FTSJ2 IQCH NEGR1 STAG3L2
Average weekly red wine intake 3.23 3 0 0.0 0.00 1.0e+00 FTSJ2 GSDMB NEGR1
Mood swings 1.45 2 0 0.0 0.00 1.0e+00 FTSJ2 SH2B3
Loneliness, isolation 1.69 1 0 0.0 0.00 1.0e+00 SH2B3
Long-standing illness, disability or infirmity 6.31 5 0 0.0 1.00 5.9e-05 IQCH NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Diabetes diagnosed by doctor 4.15 3 1 2.2 0.00 1.0e+00 FNDC4 SH2B3 STAG3L2
Qualifications: nursing, teaching 3.38 2 1 2.2 0.00 1.0e+00 NEGR1 SH2B3
Mouth/teeth dental problems: Mouth ulcers 2.17 2 0 0.0 0.00 1.0e+00 GSDMB SH2B3
Medication for cholesterol 6.35 5 2 4.4 -0.98 2.2e-03 CLCN6 FNDC4 SH2B3 STAG3L2 ZNF831
Back pain experienced in last month 1.11 1 0 0.0 0.00 1.0e+00 SH2B3
Asthma (self-reported) 18.58 6 5 11.1 0.92 8.7e-03 GSDMB IL1RL2 IQCH RP5-1029K10.2 SLC22A5 ZNF652
Osteoporosis (self-reported) 1.82 1 0 0.0 0.00 1.0e+00 FNDC4
Osteoarthritis (self-reported) 2.21 1 0 0.0 0.00 1.0e+00 RP11-295M18.6
Medication: Aspirin 4.04 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Gliclazide 1.37 1 0 0.0 0.00 1.0e+00 FNDC4
Illnesses of father: None of the above (group 1) 2.86 1 0 0.0 0.00 1.0e+00 SH2B3
Smoking status: Current 2.78 1 0 0.0 0.00 1.0e+00 STMN3
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.25 2 1 2.2 0.00 1.0e+00 GSDMB STMN3
Whole body water mass 3.62 4 3 6.7 -0.87 1.3e-01 FNDC4 NEGR1 SH2B3 SLC22A5
Leg predicted mass (right) 3.18 6 2 4.4 -0.29 5.8e-01 FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Arm fat mass (left) 3.64 5 3 6.7 0.74 1.5e-01 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Miserableness 2.91 2 1 2.2 0.00 1.0e+00 FTSJ2 GSDMB
Guilty feelings 1.63 1 0 0.0 0.00 1.0e+00 FTSJ2
Mother's age at death 2.82 1 0 0.0 0.00 1.0e+00 STAG3L2
Commuting to job workplace: Public transport 1.67 1 0 0.0 0.00 1.0e+00 NEGR1
Medication: Blood pressure 7.94 5 3 6.7 0.95 1.4e-02 CLCN6 SH2B3 STAG3L2 ZNF652 ZNF831
High cholesterol (Self-reported) 8.88 2 1 2.2 0.00 1.0e+00 CLCN6 FNDC4
Medication: Bendroflumethiazide 4.23 3 0 0.0 0.00 1.0e+00 CLCN6 SH2B3 ZNF831
Medication: Lisinopril 4.07 2 0 0.0 0.00 1.0e+00 SH2B3 ZNF831
Medication: Atorvastatin 4.59 1 1 2.2 0.00 1.0e+00 FNDC4
Illnesses of father: High blood pressure 2.73 2 0 0.0 0.00 1.0e+00 CLCN6 SH2B3
Ever smoked 2.39 4 0 0.0 1.00 8.7e-05 GSDMB IQCH SH2B3 ZNF652
Basal metabolic rate 3.50 6 3 6.7 -0.32 5.3e-01 FNDC4 IQCH NEGR1 SH2B3 SLC22A5 STAG3L2
Leg fat percentage (left) 3.55 6 3 6.7 0.78 6.5e-02 CLCN6 FTSJ2 IQCH NEGR1 STAG3L2 STMN3
Arm fat-free mass (left) 3.88 3 3 6.7 0.00 1.0e+00 FNDC4 NEGR1 SH2B3
Number of operations (self-reported) 3.45 3 0 0.0 0.00 1.0e+00 IQCH NEGR1 ZNF652
Average weekly beer plus cider intake 1.05 1 0 0.0 0.00 1.0e+00 NEGR1
Irritability 1.42 1 0 0.0 0.00 1.0e+00 FTSJ2
Fractured/broken bones in last 5 years 1.97 1 0 0.0 0.00 1.0e+00 IQCH
Age started oral contraceptive pill 1.68 1 0 0.0 0.00 1.0e+00 ZNF652
Diastolic blood pressure, automated reading 10.93 8 6 13.3 0.91 1.7e-03 CLCN6 IQCH RP5-1029K10.2 SH2B3 STAG3L2 STMN3 ZNF652 ZNF831
Ever depressed for a whole week 1.92 1 0 0.0 0.00 1.0e+00 GSDMB
Unable to work because of sickness or disability 1.72 1 0 0.0 0.00 1.0e+00 STAG3L2
Commuting to job workplace: Cycle 1.99 1 0 0.0 0.00 1.0e+00 NEGR1
Myopia 2.41 2 0 0.0 0.00 1.0e+00 FTSJ2 GSDMB
Vascular/heart problems diagnosed by doctor 12.00 10 5 11.1 -0.96 7.6e-06 CLCN6 FTSJ2 IQCH NEGR1 RP11-295M18.6 RP5-1029K10.2 SH2B3 STAG3L2 ZNF652 ZNF831
Cholesterol lowering medication 5.14 1 1 2.2 0.00 1.0e+00 FNDC4
Pain experienced in last month 1.83 1 0 0.0 0.00 1.0e+00 SH2B3
Heart attack/myocardial infarction (self-reported) 5.02 4 0 0.0 0.99 1.0e-02 RP5-1029K10.2 SH2B3 ZNF652 ZNF831
Deep venous thrombosis (DVT) (self-reported) 1.77 1 0 0.0 0.00 1.0e+00 SH2B3
Pack years of smoking 2.33 2 0 0.0 0.00 1.0e+00 STAG3L2 STMN3
Impedance of whole body 4.86 6 5 11.1 -0.42 4.1e-01 FNDC4 FTSJ2 NEGR1 RP5-1029K10.2 STAG3L2 ZNF652
Leg fat mass (left) 3.90 6 3 6.7 0.64 1.7e-01 CLCN6 FNDC4 FTSJ2 IQCH NEGR1 STAG3L2
Arm predicted mass (left) 3.84 3 3 6.7 0.00 1.0e+00 FNDC4 NEGR1 SH2B3

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 2 0.057 1.8
GTEx Adipose Visceral Omentum 0 0.000 1.7
GTEx Adrenal Gland 1 0.069 1.8
GTEx Artery Aorta 2 0.067 1.8
GTEx Artery Coronary 0 0.000 1.7
GTEx Artery Tibial 2 0.053 1.8
GTEx Brain Caudate basal ganglia 0 0.000 1.7
GTEx Brain Cerebellar Hemisphere 1 0.067 1.8
GTEx Brain Cerebellum 3 0.151 1.9
GTEx Brain Cortex 1 0.097 1.8
GTEx Brain Frontal Cortex BA9 0 0.000 1.7
GTEx Brain Hippocampus 0 0.000 1.9
GTEx Brain Hypothalamus 0 0.000 1.5
GTEx Brain Nucleus accumbens basal ganglia 1 0.116 1.7
GTEx Brain Putamen basal ganglia 0 0.000 1.6
GTEx Breast Mammary Tissue 0 0.000 1.8
GTEx Breast Mammary Tissue (Male) 1 0.084 1.7
GTEx Breast Mammary Tissue (Female) 0 0.000 1.8
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.8
GTEx Cells Transformed fibroblasts 3 0.071 1.8
GTEx Colon Sigmoid 1 0.068 1.7
GTEx Colon Transverse 1 0.048 1.8
GTEx Esophagus Gastroesophageal Junction 2 0.138 1.8
GTEx Esophagus Mucosa 0 0.000 1.8
GTEx Esophagus Muscularis 1 0.031 1.8
GTEx Heart Atrial Appendage 0 0.000 1.7
GTEx Heart Left Ventricle 0 0.000 1.7
GTEx Liver 0 0.000 1.7
GTEx Lung 2 0.070 1.7
GTEx Muscle Skeletal 1 0.035 1.8
GTEx Nerve Tibial 2 0.046 1.7
GTEx Ovary 1 0.110 1.8
GTEx Pancreas 1 0.061 1.9
GTEx Pituitary 0 0.000 1.7
GTEx Prostate 1 0.120 1.9
GTEx Skin Not Sun Exposed Suprapubic 1 0.041 1.9
GTEx Skin Sun Exposed Lower leg 2 0.055 1.8
GTEx Small Intestine Terminal Ileum 1 0.217 1.8
GTEx Spleen 0 0.000 1.8
GTEx Stomach 0 0.000 1.7
GTEx Testis 1 0.032 1.8
GTEx Thyroid 1 0.025 1.8
GTEx Uterus 1 0.176 1.7
GTEx Vagina 0 0.000 1.8
GTEx Whole Blood 1 0.050 1.9
METSIM Adipose 0 0.000 1.7
NTR Blood 0 0.000 1.7
ROSMAP Brain Pre-frontal Cortex 4 0.091 1.8
YFS Blood 1 0.022 1.7
CommonMind Brain Pre-frontal Cortex 3 0.056 1.8
The Cancer Genome Atlas Bladder Urothelial Carcinoma 1 0.060 1.8
The Cancer Genome Atlas Breast Invasive Carcinoma 1 0.023 1.7
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Colon Adenocarcinoma 1 0.048 1.7
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.7
The Cancer Genome Atlas Glioblastoma Multiforme 0 0.000 1.7
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 0 0.000 1.8
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 1 0.024 1.7
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 1 0.049 1.7
The Cancer Genome Atlas Brain Lower Grade Glioma 3 0.070 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Lung Adenocarcinoma 2 0.068 1.7
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 0 0.000 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.7
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.120 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.6
The Cancer Genome Atlas Prostate Adenocarcinoma 1 0.022 1.7
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.6
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.6
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 0 0.000 1.7
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.7
The Cancer Genome Atlas Thyroid Carcinoma 2 0.039 1.8
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.7